Antibody-suppressor CXCR5+CD8+ T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice
CXCR5
Donor-Specific Antibodies
DOI:
10.1111/ajt.16988
Publication Date:
2022-02-03T17:43:48Z
AUTHORS (16)
ABSTRACT
CCR5 KO kidney transplant (KTx) recipients are extraordinarily high alloantibody producers and develop pathology that mimics human antibody-mediated rejection (AMR). C57BL/6 mice (H-2b) were transplanted with A/J kidneys (H-2a); select cohorts received adoptive cell therapy (ACT) alloprimed CXCR5+CD8+ T cells (or control cells) on day 5 after KTx. ACT efficacy was evaluated by measuring posttransplant alloantibody, pathology, allograft survival. Recipients assessed for the quantity of CD8-mediated cytotoxicity to IgG+ B cells. Alloantibody titer in four-fold higher than recipients. The proportion 7 days KTx peripheral blood, lymph node, spleen substantially lower compared In vivo towards also reduced six-fold (but not CXCR5−CD8+ or third-party primed titer, ameliorated AMR prolonged These results indicate a deficiency function contributes recipient mice, which can be rescued ACT.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (63)
CITATIONS (10)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....